WAT — Waters Corporation

Is WAT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of November 17, 2026

Waters Corporation (WAT) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $449.51. The rating moved from Overbought to Neutral on November 16, 2026.

AI analysis

Waters Corporation benefits from a durable franchise in high-value analytical instrumentation with recurring consumables and service revenues that support cash generation and margin resilience. Near-term market conditions are calm and sector flows favor defensive/large-cap healthcare exposures, while specific themes (specialty care distribution and biopharma demand) underpin steady end-market demand for separation and mass spec systems. The main upside drivers are continued biopharma R&D spending, replacement cycles, successful commercialization of new products and potential strategic M&A. Principal risks include a pullback in lab CAPEX, competitive pressure from larger OEMs, supply-chain timing issues and currency effects. Overall, current fundamentals and structural demand signal modest upside over the next 1–4 weeks, with outcomes sensitive to execution and broader capex trends.

Key factors

  • Leading market position in chromatography and mass spectrometry with strong brand recognition in pharma, biotech and applied markets
  • High-margin consumables, services and recurring revenue that provide durable cashflow and earnings resiliency
  • Ongoing demand from biopharma R&D and quality/regulatory testing supports replacement cycles and aftermarket growth
  • Sector dynamics: distributor shift to specialty care and sustained prescription flows should support lab and biopharma service channels
  • Limited near-term macro volatility and balanced market positioning reduce downside risk in a consolidated market environment
  • Potential M&A and product-cycle catalysts that could expand addressable markets and add cross-sell opportunities

Risks

  • Slower end-market capital spending (corporate/academic lab CAPEX) in a macro slowdown that delays instrument purchases
  • Intensifying competition from larger instrument OEMs (e.g., Thermo Fisher, Agilent) pressuring pricing and share gains
  • Regulatory and reimbursement changes in adjacent healthcare sectors that indirectly affect customer budgets
  • Supply‑chain disruptions or component shortages that could push out shipments and compress near-term revenue
  • Currency/FX exposure and potential margin pressure if USD moves unfavorably or input costs rise
  • Execution risk on new product rollouts or integration risk from any acquisitions

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for WAT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.